menu
    • menu
    [{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Fourth Swedish National Pension Fund"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Oral Tablet","sponsorNew":"Cinclus Pharma \/ Zentiva","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Zentiva"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cinclus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cinclus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cinclus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cinclus Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Linaprazan Glurate

    Menu

    Linaprazan Glurate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Zentiva

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zentiva Inks €220M Deal for Former AstraZeneca GI Drug in Europe

                            Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $14.7 million

                            May 22, 2025

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Zentiva

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 24, 2023

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midaz...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 01, 2022

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 25, 2022

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 22, 2022

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Fourth Swedish National Pension Fund

                            Deal Size : $25.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophag...

                            Details : The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 03, 2020

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Fourth Swedish National Pension Fund

                            Deal Size : $25.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth